Singapore will add the HPV9 vaccine to its national immunisation schedules starting in January 2027, replacing the HPV2 vaccine for female students who have not yet completed their vaccination series.
The HPV9 vaccine, which provides broader protection against cervical cancer than HPV2, will be added to Singapore's national immunisation schedules from January 1, 2027. It will be included in both the National Childhood Immunisation Schedule (NCIS) and National Adult Immunisation Schedule (NAIS) for females aged nine to 26. The HPV9 vaccine will be fully subsidised for eligible Singaporean children, and it will also be added to the Subsidised Vaccine List, making government subsidies available for eligible Singaporeans and permanent residents. The HPV2 vaccine, also known as Cervarix, will remain on both schedules as an alternative option.
Currently, government subsidies and MediSave cannot be used for HPV9 vaccination. At Singapore Women's Clinic, for example, HPV9 currently costs S$250 per dose, more than twice the S$96 charged for the HPV2 vaccine. From January 1, 2027, eligible Singaporean children will receive full subsidies for HPV9 at CHAS GP clinics and polyclinics. Eligible Singaporean adults can receive means-tested subsidies of up to 75 per cent at these clinics, while eligible permanent residents can receive subsidies at polyclinics. MediSave use will also be extended to HPV9 for those in the recommended groups, subject to the prevailing MediSave Chronic and Preventive Care withdrawal limits.
Why it matters
HPV9 vaccine will replace HPV2 in Singapore's school immunisation programme, but a WHO regional statement does not establish a country's confirmed case count or policy outcome.
This section reflects Dumpling editorial interpretation and is provided for context only.
What to watch
Watch for wHO technical guidance and country implementation in subsequent official updates.
This section reflects Dumpling editorial interpretation and is provided for context only.